新天药业(002873) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥162,134,733.73, representing a 3.66% increase compared to ¥156,411,465.16 in the same period last year[7] - The net profit attributable to shareholders was ¥17,339,683.60, up 1.25% from ¥17,125,823.30 year-on-year[7] - The net profit for the first quarter was CNY 17,226,756.36, slightly up from CNY 17,125,823.30, indicating a growth of 0.6%[34] - The net profit for the first quarter of 2019 was CNY 20,558,987.72, an increase from CNY 19,381,596.77 in the same period last year, representing a growth of approximately 6.06%[38] - The total operating costs amounted to CNY 142,225,698.18, up from CNY 138,040,919.85, reflecting a year-over-year increase of 3.1%[32] - The total operating expenses amounted to CNY 174,279,686.57, compared to CNY 161,748,633.60 in the previous year, indicating an increase in operational costs[42] Cash Flow - The net cash flow from operating activities surged by 2,137.85%, reaching ¥30,027,733.48 compared to ¥1,341,814.45 in the previous year[7] - The cash flow from operating activities showed a net increase of CNY 30,027,733.48, significantly higher than CNY 1,341,814.45 in the same quarter of the previous year[42] - The net cash flow from operating activities for the first quarter was CNY 54,469,396.19, a significant increase from CNY 17,834,802.01 in the same period last year, representing a growth of approximately 205.5%[46] - The company reported a total cash outflow from operating activities of CNY 149,811,988.77, slightly higher than CNY 145,245,421.35 in the previous year[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥977,057,400.45, a decrease of 0.74% from ¥984,313,099.51 at the end of the previous year[7] - The company's total assets reached CNY 991,627,184.48, compared to CNY 979,222,347.52 at the end of the previous period, marking an increase of 1.5%[31] - Total liabilities decreased to RMB 308,765,758.82 from RMB 323,724,363.99, showing a decline of about 4.6%[25] - The total liabilities were CNY 323,559,499.44, a marginal increase from CNY 322,189,799.95, reflecting a growth of 0.4%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,044[10] - The company repurchased a total of 1,582,500 shares, accounting for 1.35% of the total share capital, with a maximum transaction price of RMB 16.99 per share and a minimum of RMB 15.52 per share[15] Expenses - Management expenses rose by 35.03% to ¥23,486,604.05, primarily due to an increase in personnel and salary adjustments[14] - Research and development expenses for the quarter were CNY 4,615,701.14, down from CNY 5,113,223.57, indicating a decrease of 9.8%[32] - The company paid CNY 27,941,967.53 in employee compensation, an increase from CNY 24,531,335.45 in the same quarter last year[42] Government Support - The company received government subsidies amounting to ¥512,769.75, which was a 36.19% increase from the previous year[14] Prepayments and Investments - The company's prepayments increased by 44.38%, totaling ¥36,527,788.42, mainly due to increased prepayments for housing and equipment[14] - The long-term equity investments increased to CNY 22,675,001.00 from CNY 15,675,001.00, representing a significant growth of 44.6%[30] Cash and Cash Equivalents - The company's cash and cash equivalents decreased to RMB 127,101,008.13 from RMB 139,247,465.31 at the end of 2018, reflecting a decline of approximately 8.2%[23] - The ending balance of cash and cash equivalents was CNY 106,520,712.26, compared to CNY 85,930,759.81 at the end of the same quarter last year, reflecting an increase of about 23.9%[47] Compliance and Audit - The company has no overdue commitments or non-compliance issues reported during the period[16] - The company did not conduct an audit for the first quarter report[48]